Cleared Traditional

K102286 - CRAG LATERAL FLOW ASSAY (CRAG LFA)

K102286 is the FDA 510(k) clearance for CRAG LATERAL FLOW ASSAY (CRAG LFA) by Immuno-Mycologics, Inc.. It is a Class 2 Microbiology device (product code GMD) cleared through the Traditional 510(k) pathway after a 342-day FDA review.

K102286 · Immuno-Mycologics, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2011
Decision
342d
Days
Class 2
Risk

K102286 is an FDA 510(k) clearance for the CRAG LATERAL FLOW ASSAY (CRAG LFA). Classified as Antisera, Latex Agglutination, Cryptococcus Neoformans (product code GMD), Class II - Special Controls.

Submitted by Immuno-Mycologics, Inc. (Norman, US). The FDA issued a Cleared decision on July 20, 2011 after a review of 342 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3165 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Immuno-Mycologics, Inc. devices

Submission Details

510(k) Number K102286 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 12, 2010
Decision Date July 20, 2011
Days to Decision 342 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
240d slower than avg
Panel avg: 102d · This submission: 342d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GMD Antisera, Latex Agglutination, Cryptococcus Neoformans
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3165
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - GMD Antisera, Latex Agglutination, Cryptococcus Neoformans

Devices cleared under the same product code (GMD) and FDA review panel - the closest regulatory comparables to K102286.
CRYPTO-LEX SYSTEM
K930418 · Trinity Laboratories, Inc. · Feb 1994
(CALAS(TM)) W/ADD'L REAGENT CALAS(TM) PRONASE
K894845 · Meridian Diagnostics, Inc. · Sep 1989
CRYPTOCOCCUS NEOFORMANS ANTISERUM, LATEX
K792693 · Meridian Diagnostics, Inc. · Jan 1980
CRYPTOCOCCAL ANTIGEN LATEX AGG. SYSTEM
K780526 · I M, Inc. · Apr 1978